Detalhe da pesquisa
1.
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia.
Blood
; 141(6): 634-644, 2023 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36219880
2.
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
Blood
; 137(20): 2721-2735, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33824975
3.
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.
Nature
; 538(7626): 477-482, 2016 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-27760111
4.
Androgens stimulate erythropoiesis through the DNA-binding activity of the androgen receptor in non-hematopoietic cells.
Eur J Haematol
; 105(3): 247-254, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32311143
5.
Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.
Blood
; 122(5): 738-48, 2013 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23775716
6.
Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers.
Cancer Cell
; 42(5): 850-868.e9, 2024 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38670091
7.
Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death.
Cancer Discov
; 12(3): 774-791, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34862195
8.
Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid Leukemia.
Cancer Discov
; 11(6): 1582-1599, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33436370
9.
Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models.
Blood Adv
; 4(20): 5062-5077, 2020 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33080008
10.
Cotargeting BCL-2 and MCL-1 in high-risk B-ALL.
Blood Adv
; 4(12): 2762-2767, 2020 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32569380
11.
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
Leukemia
; 33(4): 905-917, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30214012
12.
Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia.
Cell Stem Cell
; 25(2): 258-272.e9, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31374198
13.
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.
Cancer Discov
; 8(12): 1582-1597, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30254093
14.
Inhibition of fibroblast growth factor receptor signaling attenuates atherosclerosis in apolipoprotein E-deficient mice.
Arterioscler Thromb Vasc Biol
; 26(8): 1845-51, 2006 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16709940
15.
The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study.
Oncotarget
; 8(32): 52269-52280, 2017 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28881728
16.
The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.
Sci Transl Med
; 8(339): 339ra69, 2016 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-27194727
17.
Darbepoetin-mediated cardioprotection after myocardial infarction involves multiple mechanisms independent of erythropoietin receptor-common beta-chain heteroreceptor.
Br J Pharmacol
; 160(8): 2085-96, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20649603
18.
A novel antioxidant 3,7-dihydroxy-isoflav-3-ene (DHIF) inhibits neointimal hyperplasia after vessel injury attenuating reactive oxygen species and nuclear factor-kappaB signaling.
Atherosclerosis
; 204(1): 66-72, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18930230